ASH 2010 Conference Coverage

FOLFIRI treatment response not related to colorectal cancer classification by gene expression

The current classification system for colorectal cancer, based on genetic profiles, cannot be used to predict drug responses to FOLFIRI.

First targeted treatment to boost survival for esophageal cancer

Patients with a specific type of esophageal cancer survived longer when they were given the latest lung cancer drug, according to trial results.

Fecal testing shows effectiveness for screening of familial colorectal cancer

Fecal immunochemical tests may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer.

Exercise therapy benefits breast cancer survivors

Exercise offers several benefits for breast cancer survivors, including reduced symptoms of lymphedema, according to a new study.

CT lung screening appears cost-effective

A new statistical analysis of results from the National Lung Screening Trial concludes that performing low-dose computerized tomography (CT) screening can be cost-effective.

Collaboration yields new methods to treat tumors with antennas

Two engineering researchers have challenged a commonly held idea about tumor ablation.

Classifying gene mutations in neuroblastoma may point to improved treatments

Oncology researchers studying gene mutations in the childhood cancer neuroblastoma are refining their diagnostic tools to predict which patients are more likely to respond to the drugs that target these mutations.

International study shows wide differences in 5-year survival rates across the globe

There are very large differences in 5-year survival among patients with cancer between 67 countries.

Overweight and obesity status causes nearly half a million new cancer cases each year

Nearly half a million new cases of cancer each year are a result of high body mass index (BMI).

Diagnostic grading system developed for cancer-related weight loss

New grading system for cancer-linked weight loss includes independent prognostic significance of BMI and percent weight loss.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs